99mTc-EDDA/HYNIC-TOC is a New Opportunity in Neuroendocrine Tumors of the Lung (and in other Malignant and Benign Pulmonary Diseases)
| Autor: | Flavia Linguanti, Vittorio Briganti, Valentina Berti, Francesco Mungai, Luigi Mansi, Giuseppe Danilo Di Stasio, Vincenzo Cuccurullo |
|---|---|
| Přispěvatelé: | Briganti, Vittorio, Cuccurullo, Vincenzo, Berti, Valentina, Di Stasio, Giuseppe Danilo, Linguanti, Flavia, Mungai, Francesco, Mansi, Luigi |
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Oncology
medicine.medical_specialty PET/CT diagnostic imaging Carcinoid tumors Neuroendocrine tumors somatostatin Article lung Neuroendocrine tumor Internal medicine medicine Neoplasm Radiology Nuclear Medicine and imaging nuclear medicine Lung cancer Pharmacology Lung Somatostatin receptor business.industry medicine.disease medicine.anatomical_structure Radionuclide therapy 99mTc-EDDA/HYNIC-TOC Differential diagnosis business |
| Zdroj: | Current Radiopharmaceuticals |
| ISSN: | 1874-4729 1874-4710 |
| Popis: | Neuroendocrine tumors (NETs) consist of a relatively rare spectrum of malignancies that can arise from neuroendocrine cells; lung NETs (L-NETs) represent about 25% of primary lung neoplasm and 10% of all carcinoid tumors. Diagnostic algorithm usually takes into consideration chest Xray, contrast-enhanced CT and MRI. Nuclear medicine plays a crucial role in the detection and correct assessment of neoplastic functional status as it provides in vivo metabolic data related to the overexpression of Somatostatin Receptors (SSTRs) and also predicting response to peptide receptor radionuclide therapy (PRRT). 111In-Pentreotide (Octreoscan®) is commercially available for imaging of neuroendocrine tumors, their metastases and the management of patients with NETs. More recently, 99mTc-EDDA/HYNIC-TOC(Tektrotyd®) was introduced into the market and its use has been approved for imaging of patients with L-NETs and other SSTR-positive tumors. 99mTc-EDDA/HYNIC-TOC could also represent a good alternative to 68Ga-DOTA-peptides (DOTA-TOC, DOTA-NOC, DOTATATE) in hospitals or centers where PET/CT or 68Ge/68Ga generators are not available. When compared to 111In-Pentetreotide, Tektrotyd® showed slightly higher sensitivity, in the presence of higher imaging quality and lower radiation exposure for patients. Interesting perspectives depending on the kinetic analysis allowed by Tektrotyd® may be obtained in differential diagnosis of non-small cells lung cancer (NSCLC) versus small cells lung cancer (SCLC) and NETs. An interesting perspective could be also associated with a surgery radio-guided by Tektrotyd® in operable lung tumors, including either NETs and NSCLC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|